Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.43 |
| ▸ | CA12 | O43570 | 4/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.43 |
| ▸ | CA9 | Q16790 | 4/20 | 0.43 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.39 |
| ▸ | PKM | P14618 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28019147 | 1.00 | CA2 (0.43) | CA2CA12CA1CA9VCAM1 | |
| SCHEMBL28019154 | 1.00 | CA2 (0.43) | CA2CA12CA1CA9VCAM1 | |
| SCHEMBL1700530 | 0.81 | MAPT (0.58) | MAPTPKMALDH1A1KMT2AMEN1 | |
| SCHEMBL1700127 | 0.81 | MAPT (0.58) | MAPTPKMALDH1A1KMT2AMEN1 | |
| SCHEMBL1700052 | 0.81 | MAPT (0.58) | MAPTPKMALDH1A1KMT2AMEN1 | |
| SCHEMBL1700347 | 0.81 | HTR2A (0.46) | CA2CA12CA1CA9VCAM1 | |
| SCHEMBL31525113 | 0.81 | MAPT (0.58) | MAPTPKMALDH1A1KMT2AMEN1 | |
| SCHEMBL28019169 | 0.79 | CA2 (0.45) | CA2CA12CA1CA9VCAM1 | |
| SCHEMBL23064497 | 0.78 | KCNH2 (0.36) | CA2CA12CA1CA9 | |
| SCHEMBL27910634 | 0.75 | MAPT (0.47) | CA2CA12CA1CA9VCAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109966294-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 艾伯维爱尔兰无限公司 | 2019-07-05 | — | — | CN | disclosed |
| CN-109897038-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 艾伯维爱尔兰无限公司 | 2019-06-18 | — | — | CN | disclosed |
| CN-106008322-B | sulfonamide derivatives as BC L-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | ABBVIE 公司 | 2018-09-04 | — | — | CN | disclosed |
| CN-108175749-A | The solid dispersions of melt extrusion containing cell death inducer | 艾伯维爱尔兰无限公司 | 2018-06-19 | — | — | CN | disclosed |
| CN-103282025-B | Melt-extruded solid dispersions containing apoptosis-inducing agents | 艾伯维爱尔兰无限公司 | 2018-01-02 | — | — | CN | disclosed |
| CN-104876927-B | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 艾伯维爱尔兰无限公司 | 2017-06-23 | — | — | CN | disclosed |
| CN-103167867-B | Solid dispersion containing apoptosis-inducing medicament | ABBVIE 公司 | 2016-12-21 | — | — | CN | disclosed |
| CN-106008322-A | BCL-2-selectively apoptosis-inducing agents for the treatment of cancer and immune diseases | ABBVIE 公司 | 2016-10-12 | — | — | CN | disclosed |
| CN-103153993-B | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (BS) | 2016-06-01 | — | — | CN | disclosed |
| CN-104906100-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LAB | 2015-09-16 | — | — | CN | disclosed |
| CN-104876927-A | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LAB | 2015-09-02 | — | — | CN | disclosed |
| CN-102947285-B | Sulfonamide derivatives as BCL-2-selective apoptosis inducers for the treatment of cancer and immune diseases | ABBVIE (US) | 2015-08-26 | — | — | CN | disclosed |
| CN-102448959-B | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE BAHAMAS LTD | 2015-06-17 | — | — | CN | disclosed |